<DOC>
	<DOCNO>NCT00931450</DOCNO>
	<brief_summary>RATIONALE : Sunitinib malate exemestane may stop growth tumor cell block enzymes need cell growth . Giving sunitinib malate exemestane surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This randomized phase I/II trial study side effect best dose sunitinib malate see well work give together exemestane treat postmenopausal woman breast cancer .</brief_summary>
	<brief_title>Sunitinib Malate Exemestane Treating Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safe dose level sunitinib malate combine exemestane ( pilot phase I ) . - Evaluate clinical response neoadjuvant therapy comprise exemestane sunitinib malate postmenopausal woman hormone receptor-positive HER-2 negative primary breast cancer ( phase II ) . Secondary - Evaluate safety feasibility regimen patient . - Evaluate percentage patient undergo breast-conserving surgery completion study therapy . - Determine safety profile regimen patient . - Determine rate complete pathological response breast axillary lymph node time surgery . - Determine extent treatment-related inhibition phosphorylation VEGFR-2 , PDGF , c-KIT receptor tyrosine kinase . - Find genetic profile , base analysis CYP19A1 polymorphism , able predict response exemestane neoadjuvant setting . - Conduct exploratory investigation biomarkers expression therapy order identify molecular characteristic respond tumor . OUTLINE : This multicenter , dose-escalation study sunitinib malate follow phase II study . - Phase I pilot : Patients receive oral sunitinib malate oral exemestane daily day 1-28 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Phase II : Patients randomize 1 2 treatment group : - Group 1 : Patients receive oral exemestane oral placebo daily day 1-28 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Group 2 : Patients receive oral exemestane daily oral sunitinib malate daily day 1-28 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . At 7-15 day completion study therapy , patient undergo definitive surgery . Blood tissue sample collect baseline periodically study examine inhibition phosphorylation VEGFR-2 , PDGF , c-KIT receptor tyrosine kinases ; CYP19A1 polymorphisms ; biomarkers analysis cDNA microarrays , ELISA , RT-PCR .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast carcinoma meeting follow criterion : Estrogen receptorpositive ≥ 50 % Allred score &gt; 6 HER2 negative define IHC &lt; 2+ negative FISH/CISH Primary tumor measure ≥ 3 cm node involvement Any T N1 N2 disease No inflammatory breast cancer ( T4d ) No metastatic disease Measurable disease mammography and/or ultrasound MRI ( available ) PATIENT CHARACTERISTICS : Postmenopausal Prior bilateral oophorectomy ≥ 60 year age &lt; 60 year age AND experience amenorrhea ≥ 12 month absence chemotherapy , tamoxifen , toremifene OR undergone ovarian suppression folliclestimulating hormone estradiol level postmenopausal range ECOG performance status 01 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Albumin &gt; 2.5. g/dL No known HIV infection Adequate leave ventricular ejection fraction ( LVEF ) baseline define LVEF normal range echocardiogram MUGA No evidence prior uncontrolled hypertension Patients control hypertension ( systolic &lt; 150 mm Hg and/or diastolic &lt; 90 mm Hg ) antihypertensive therapy allow No prior uncontrolled symptomatic angina , myocardial infarction , congestive heart failure , clinically significant arrhythmia , prolongation QTc interval No hemorrhagic thrombotic event , include transient ischemic attack , pulmonary embolism , deepvein thrombosis , within past 12 month No gross hemorrhage within past 6 month ( e.g. , gastrointestinal bleeding , hemoptysis , hematuria ) No history evidence inherit bleed diathesis coagulopathy risk bleed None following : Unable swallow oral medication Active inflammatory bowel disease Partial complete bowel obstruction Chronic diarrhea No history another malignancy within past 5 year except cured nonmelanoma skin cancer successfully treat carcinoma situ cervix No psychiatric disease social situation would limit compliance study requirement patient unwilling unable comply protocol duration study No unstable severe intercurrent medical condition , opinion investigator , might interfere achievement study objectives No known immediate delay hypersensitive reaction idiosyncrasy drug chemically relate exemestane sunitinib malate excipients PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior concurrent chemotherapy , radiotherapy , immunotherapy , biologic therapy , hormonal therapy primary invasive breast cancer No concurrent anticoagulant therapy except lowdose anticoagulant ( i.e. , low molecular weight heparin aspirin ) prevention deepvein thrombosis No chronic therapy corticosteroid , except steroid administer inhalation More 4 week since prior major surgery ≥ 7 day since prior minor surgery No prior concurrent investigational anticancer agent No concurrent participation another clinical trial No concurrent drug potential proarrhythmic activity No concurrent know CYP3A4 inhibitor ( i.e. , grapefruit , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , clarithromycin , diltiazem , nefazodone , voriconazole , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , delavirdine ) No concurrent know CYP3A4 CYP1A2 inducer ( i.e. , carbamazepine , dexamethasone , felbamate , omeprazole , efavirenz , tipranavir , phenobarbital , phenytoin , primidone , rifabutin , rifampicin , St. John 's wort )</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>